SCHEMBL6138905

SCHEMBL6138905

COCCOCCOC(=O)CCCCC(=O)c1ccc(-c2nc3ccccc3o2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.54
HPGD P15428 4/20 0.54
ALDH1A1 P00352 4/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
HSD17B10 Q99714 3/20 0.54
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
KDM4E B2RXH2 2/20 0.54
MEN1 O00255 1/20 0.46
USP2 O75604 1/20 0.46
GAA P10253 1/20 0.46
TSHR P16473 1/20 0.46
STAT3 P40763 1/20 0.46
KMT2A Q03164 1/20 0.46
TP53 P04637 5/20 0.45
RXFP1 Q9HBX9 1/20 0.44
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6138955 0.89 MAPT (0.49) MAPTHPGDALDH1A1SMN1; SMN2HSD17B10
SCHEMBL6138900 0.75 HDAC1 (0.49) MAPTHPGDALDH1A1SMN1; SMN2NPC1
SCHEMBL6138941 0.73 HAO1 (0.44) MAPTALDH1A1HDAC1HDAC8CYP3A4
SCHEMBL3372495 0.71 MAPT (1.00) MAPTHPGDALDH1A1SMN1; SMN2HSD17B10
SCHEMBL19533679 0.70 MAPT (0.61) MAPTHPGDALDH1A1SMN1; SMN2HSD17B10
SCHEMBL11136257 0.69 HPGD (0.68) MAPTHPGDALDH1A1SMN1; SMN2HSD17B10
SCHEMBL6138949 0.69 TNFRSF1A (0.37) MAPTALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL9680824 0.69 NPC1 (0.72) MAPTHPGDALDH1A1SMN1; SMN2HSD17B10
SCHEMBL15739478 0.69 MAPT (0.71) MAPTHPGDALDH1A1SMN1; SMN2HSD17B10
SCHEMBL28510537 0.68 NPC1 (0.53) MAPTHPGDALDH1A1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1215203-B1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2005-02-16 EP disclosed
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient ONO PHARMACEUTICAL CO., LTD. 2004-10-28 US disclosed
US-6770644-B1 Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient ONO PHARMACEUTICALS CO., LTD. (JP) 2004-08-03 US disclosed
EP-1215203-A1 HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214896-A1 Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient HIF1AN, IL6, PYGM MAPT 3517/4885HPGD 214/4885ALDH1A1 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.